iNtODEWORLD | President Message
16460
page,page-id-16460,page-template,page-template-full_width,page-template-full_width-php,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

All creatures have their chromosomes, which are composed of a combination of EXON and INTRON.

 

Before the BIO revolution called “Human Genome Project”, it was believed that EXON was the most important part. However, after this project was completed and the Biotech industry flourished, the importance of INTRON became widely recognized. There continues to be extensive research on the importance of INTRON today.

 

iNtRON Bio, Inc. originated from the concept of INTRON itself. iNtRON Bio, Inc. strives to be the true worldwide leader in biotechnology in life engineering. The company was established based on this goal and it remains the vision of iNtRON Bio, Inc. to this day. And more, iNtRON’s “it” contains our dream and vision.

 

iNtRON Bio, Inc. started as a research reagents company in 1999. Later, the molecular diagnostic business as added. The company became a leading diagnostic company which was renowned for its New Flu diagnostic Kit. And then, after developing platform technology related to Bacteriophage and Endolysin, the company passed a technology evaluation by the Korea Exchange (KRX) in 2010. Then in January 2011, iNtRON Bio, Inc. finally had its first IPO and was listed on the KOSDAQ. The company is continuously searching for ways to improve and innovate in pursuit of its goal of becoming the world’s best biotechnology company.

 

After going public, the company once again questioned its prospects for longevity and sustained growth.
iNtRON is now focusing on becoming a Global Leader in Research and Development. We believe this R&D based investment will enable us to become a “Global R&D Group”. We are committed to becoming a leading “Global R&D Group”.

 

iNtRON’s New Drug R&D is focused on 1) Humans 2) Medicines for Diseases 3) First-in-Class (MOA based)

 

iNtRON Bio, Inc. is continuously striving to develop not only new Blockbuster drugs, but new Moral-Buster drugs as well. In addition to that, the new drug technology used as a base for this development will focus on discovering First-in-Class new drug candidate substances which MOA proves.

 

With the belief that “Only Passion Makes Me Free!” and “不狂不及, 磨斧作針, 熱血男兒” spirit we will become a leading “Global R&D Group”, who, based on our dedication and tireless effort, will show exceptional results on a continuous basis.

August 2017
Seong Jun Yoon
CEO/President
iNtRON Biotechnology, Inc
iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.